Penumbra shares surge as thrombectomy leader beats Q2 expectations

Published 29/07/2025, 21:36
Penumbra shares surge as thrombectomy leader beats Q2 expectations

Investing.com -- Penumbra, Inc. (NYSE:PEN), a leading thrombectomy company, reported second quarter earnings that exceeded analyst expectations, driving shares up 7% following the announcement.

The medical device maker posted revenue of $339.5 million for the second quarter of 2025, surpassing the consensus estimate of $327.77 million and representing a 13.4% increase compared to the same period last year. Adjusted earnings per share came in at $0.86, beating analyst expectations of $0.83.

Penumbra’s U.S. thrombectomy business was the standout performer, with revenue jumping 22.6% YoY to $188.5 million. The company’s U.S. venous thromboembolism (VTE) revenue showed particularly strong growth, increasing 42% compared to the second quarter of 2024.

"Our second quarter results demonstrate the continued strength of our thrombectomy portfolio, particularly in the U.S. market," said Adam Elsesser, CEO of Penumbra. "The exceptional growth in our VTE business reflects the increasing adoption of our innovative technologies by physicians treating patients with blood clots."

The company reported income from operations of $40.8 million, representing an operating margin of 12.0%. Net income reached $45.3 million with a net income margin of 13.3%.

Based on the strong performance, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.37 billion, above the consensus estimate of $1.354 billion. This updated outlook represents growth of 13% to 15% over 2024 revenue. The company maintained its guidance for U.S. thrombectomy growth of 20% to 21% compared to 2024 levels.

International sales declined 3.2% (or 5.8% in constant currency) during the quarter, while U.S. revenue, which accounted for 76.8% of total sales, increased by 19.5%.

Gross profit for the quarter was $224.0 million, or 66.0% of total revenue, compared to 54.4% in the same period last year, with the improvement driven by favorable product mix and productivity enhancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.